New asccp guidelines include more precise method of cervical cancer screening

Bd onclarity™ hpv assay adheres to new guidelines by identifying more individual types of hpv than any other test on the market franklin lakes, n.j. , jan. 13, 2025 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced that the bd onclarity™ hpv assay has officially been added to the american society for colposcopy and cervical pathology (asccp) enduring risk-based management guidelines, due to its ability to individually identify more high-risk types of hpv.
BDX Ratings Summary
BDX Quant Ranking